LAE-32

LAE-32

Clinical data
Other names	LAE, Lysergic acid ethylamide, d-lysergic acid ethylamide, d-ethyllysergamide,
Routes of administration	Oral
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
IUPAC name (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
CAS Number	478-99-9 Y
PubChem CID	101704
ChemSpider	19975296 Y
UNII	72370WPF0J
CompTox Dashboard (EPA)	DTXSID20963946
Chemical and physical data
Formula	C18H21N3O
Molar mass	295.386 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCNC(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C)C2)c34
InChI InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1 Y Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N Y
(verify)

D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.